Surgery Partners' (SGRY) "Buy" Rating Reiterated at Benchmark

Surgery Partners (NASDAQ:SGRY - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Benchmark in a note issued to investors on Monday,Benzinga reports. They presently have a $35.00 price objective on the stock. Benchmark's price objective would indicate a potential upside of 62.94% from the company's current price.

Several other brokerages have also issued reports on SGRY. Royal Bank of Canada reissued an "outperform" rating and set a $35.00 target price on shares of Surgery Partners in a research note on Tuesday, March 25th. Macquarie cut their price objective on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $34.75.

Surgery Partners Trading Down 1.6 %

Shares of SGRY stock traded down $0.36 during mid-day trading on Monday, hitting $21.48. The company's stock had a trading volume of 846,186 shares, compared to its average volume of 1,098,909. The company has a market cap of $2.74 billion, a PE ratio of -44.75, a P/E/G ratio of 19.21 and a beta of 2.40. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The company's fifty day simple moving average is $23.07 and its 200-day simple moving average is $24.10. Surgery Partners has a 52 week low of $19.50 and a 52 week high of $33.97.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.38 by $0.01. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The business had revenue of $864.40 million during the quarter, compared to analysts' expectations of $828.09 million. As a group, equities research analysts expect that Surgery Partners will post 0.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Marissa Brittenham sold 3,156 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the sale, the insider now directly owns 63,408 shares of the company's stock, valued at approximately $1,527,498.72. This represents a 4.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Harrison R. Bane sold 56,315 shares of Surgery Partners stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the transaction, the insider now directly owns 107,037 shares in the company, valued at $2,744,428.68. This represents a 34.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 106,622 shares of company stock worth $2,717,860 in the last quarter. Insiders own 2.30% of the company's stock.

Hedge Funds Weigh In On Surgery Partners

Several hedge funds have recently modified their holdings of SGRY. KBC Group NV increased its position in shares of Surgery Partners by 66.1% during the fourth quarter. KBC Group NV now owns 3,962 shares of the company's stock valued at $84,000 after acquiring an additional 1,577 shares during the last quarter. State of Wyoming boosted its holdings in shares of Surgery Partners by 94.4% in the 4th quarter. State of Wyoming now owns 4,002 shares of the company's stock worth $85,000 after buying an additional 1,943 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in Surgery Partners by 12.1% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,296 shares of the company's stock valued at $91,000 after buying an additional 465 shares during the period. GAMMA Investing LLC increased its holdings in Surgery Partners by 7,902.7% during the first quarter. GAMMA Investing LLC now owns 8,883 shares of the company's stock worth $211,000 after buying an additional 8,772 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC raised its position in Surgery Partners by 16.6% in the fourth quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock worth $218,000 after acquiring an additional 1,460 shares during the period.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.